Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATOSOTCMKTS:AYRWFNASDAQ:LYELNASDAQ:THTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATOSAtossa Therapeutics$0.83-4.4%$0.75$0.55▼$1.66$107.43M1.01786,272 shs608,937 shsAYRWFAyr Wellness$0.23-4.8%$0.20$0.12▼$2.60$26.84M1.84276,289 shs21,450 shsLYELLyell Immunopharma$0.42-1.0%$0.46$0.39▼$2.85$123.48M-0.251.03 million shs527,077 shsTHTXTheratechnologies$2.64+1.9%$2.22$1.12▼$3.13$121.39M0.56807,859 shs87,075 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATOSAtossa Therapeutics-4.39%-14.27%+12.70%+4.59%-45.64%AYRWFAyr Wellness-4.82%-3.75%+33.68%-42.68%-90.76%LYELLyell Immunopharma-1.02%+0.75%-12.53%-40.33%-84.85%THTXTheratechnologies+1.93%+1.15%-2.22%+43.09%+107.87%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATOSAtossa Therapeutics2.0369 of 5 stars3.52.00.00.03.11.70.0AYRWFAyr Wellness2.3484 of 5 stars3.35.00.00.01.10.01.3LYELLyell Immunopharma2.9311 of 5 stars2.82.00.00.02.85.01.3THTXTheratechnologiesN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATOSAtossa Therapeutics 3.00Buy$7.13756.68% UpsideAYRWFAyr Wellness 2.50Moderate Buy$3.001,198.70% UpsideLYELLyell Immunopharma 1.50Reduce$1.00139.18% UpsideTHTXTheratechnologies 4.00Strong BuyN/AN/ACurrent Analyst Ratings BreakdownLatest AYRWF, ATOS, LYEL, and THTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/21/2025ATOSAtossa TherapeuticsAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$7.00 ➝ $7.254/16/2025LYELLyell ImmunopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$1.00 ➝ $1.004/11/2025THTXTheratechnologiesJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Strong-Buy3/26/2025ATOSAtossa TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $7.003/13/2025LYELLyell ImmunopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$1.00 ➝ $1.003/12/2025ATOSAtossa TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $7.003/7/2025AYRWFAyr WellnessVentum Cap MktsSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATOSAtossa TherapeuticsN/AN/AN/AN/A$0.73 per shareN/AAYRWFAyr Wellness$463.63M0.06$0.03 per share7.43$7.39 per share0.03LYELLyell Immunopharma$65K1,899.70N/AN/A$2.60 per share0.16THTXTheratechnologies$88.67M1.37N/AN/A($0.45) per share-5.87Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATOSAtossa Therapeutics-$30.09M-$0.21N/AN/AN/AN/A-35.74%-33.51%8/11/2025 (Estimated)AYRWFAyr Wellness-$272.43M-$3.26N/AN/AN/A-48.17%-25.30%-9.94%N/ALYELLyell Immunopharma-$234.63M-$1.25N/AN/AN/A-323,792.09%-34.64%-30.02%8/6/2025 (Estimated)THTXTheratechnologies-$23.96M-$0.08N/A37.71N/A-3.75%N/A-4.31%7/9/2025 (Estimated)Latest AYRWF, ATOS, LYEL, and THTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025ATOSAtossa Therapeutics-$0.06-$0.05+$0.01-$0.05N/AN/A5/13/2025Q1 2025LYELLyell Immunopharma-$0.19-$0.18+$0.01-$0.18N/A$0.01 million3/25/2025Q4 2024ATOSAtossa Therapeutics-$0.0633-$0.05+$0.0133-$0.05N/AN/A3/12/2025Q4 2024LYELLyell Immunopharma-$0.20-$0.72-$0.52-$0.72N/A$0.01 million3/6/2025Q4 2024AYRWFAyr Wellness-$0.29-$0.41-$0.12-$1.40$114.10 million$113.96 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATOSAtossa TherapeuticsN/AN/AN/AN/AN/AAYRWFAyr WellnessN/AN/AN/AN/AN/ALYELLyell ImmunopharmaN/AN/AN/AN/AN/ATHTXTheratechnologiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATOSAtossa TherapeuticsN/A13.3013.30AYRWFAyr Wellness0.761.590.58LYELLyell ImmunopharmaN/A13.4313.43THTXTheratechnologiesN/A1.080.97Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATOSAtossa Therapeutics12.74%AYRWFAyr Wellness0.91%LYELLyell Immunopharma66.05%THTXTheratechnologiesN/AInsider OwnershipCompanyInsider OwnershipATOSAtossa Therapeutics7.60%AYRWFAyr Wellness8.10%LYELLyell Immunopharma25.10%THTXTheratechnologiesN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATOSAtossa Therapeutics8129.17 million116.24 millionOptionableAYRWFAyr Wellness2,380116.19 million106.77 millionNot OptionableLYELLyell Immunopharma270295.34 million218.83 millionOptionableTHTXTheratechnologies14045.98 millionN/AOptionableAYRWF, ATOS, LYEL, and THTX HeadlinesRecent News About These CompaniesTheratechnologies (NASDAQ:THTX) Trading Up 0.5% - Here's WhyMay 10, 2025 | marketbeat.comTheratechnologies (NASDAQ:THTX) Trading Up 0.5% - Here's What HappenedMay 10, 2025 | marketbeat.comTheratechnologies announces annual shareholder meetingMay 4, 2025 | uk.investing.comTheratechnologies Presents Novel Data at ACTHIV 2025 Underscoring Importance of Managing Excess Visceral Abdominal Fat (EVAF) in People with HIVMay 2, 2025 | globenewswire.comTheratechnologies: A High-Risk, High-Reward Speculation As Shares Trade At 39% Discount To Future Pak's $3.51-$4.50 OfferApril 18, 2025 | seekingalpha.comIs Theratechnologies Inc. (THTX) the Best Rising Penny Stock to Buy According to Analysts?April 18, 2025 | msn.comTheratechnologies to further evaluate potential sale of the companyApril 16, 2025 | markets.businessinsider.comTheratechnologies Provides Update on Sale ProcessApril 15, 2025 | financialpost.comTheratechnologies Provides Update on Sale ProcessApril 15, 2025 | globenewswire.comTheratechnologies Engages in Exclusive Acquisition TalksApril 15, 2025 | tipranks.comSoleus Capital Issues Letter to The Board of TheratechnologiesApril 12, 2025 | financialpost.comSoleus Capital Issues Letter to The Board of TheratechnologiesApril 12, 2025 | businesswire.comTheratechnologies Responds to Future Pak's Press Release and Announces Exclusive Discussions with Another Potential Acquiror for the Sale of the CompanyApril 11, 2025 | globenewswire.comFuture Pak submits proposals to acquire TheratechnologiesApril 11, 2025 | msn.comFuture Pak Submits Proposals to Acquire Theratechnologies Inc. ...April 11, 2025 | gurufocus.comFuture Pak Submits Proposals to Acquire Theratechnologies Inc., Offering up to $255 Million in Total ValueApril 11, 2025 | businesswire.comTheratechnologies Stock Plummets On Disappointing Q1 Earnings, Full Year Forecast: Retail Sentiment SoursApril 9, 2025 | msn.comTheratechnologies Reports Financial Results for the First Quarter 2025 and Reviews Key AchievementsApril 9, 2025 | globenewswire.comTheratechnologies Reports Financial Results for the First Quarter 2025 and Reviews Key AchievementsApril 9, 2025 | globenewswire.comTheratechnologies receives FDA approval of PAS for EGRIFTA SV sBLAApril 8, 2025 | markets.businessinsider.com3THTX : Examining the Future: Theratechnologies's Earnings OutlookApril 8, 2025 | benzinga.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAYRWF, ATOS, LYEL, and THTX Company DescriptionsAtossa Therapeutics NASDAQ:ATOS$0.83 -0.04 (-4.39%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$0.84 +0.01 (+0.64%) As of 05/23/2025 06:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.Ayr Wellness OTCMKTS:AYRWF$0.23 -0.01 (-4.82%) As of 05/23/2025 03:56 PM EasternAyr Wellness Inc. operates as a vertically-integrated multi-state cannabis operator that cultivates, manufactures, and retails cannabis products and branded cannabis packaged goods. It owns and operates a chain of cannabis retail stores under AYR, Liberty Health Sciences, and The Dispensary brand names. The company was formerly known as Ayr Strategies Inc. and changed its name to Ayr Wellness Inc. in February 2021. Ayr Wellness Inc. was incorporated in 2017 and is headquartered in Miami, Florida.Lyell Immunopharma NASDAQ:LYEL$0.42 0.00 (-1.02%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$0.41 -0.01 (-1.46%) As of 05/23/2025 05:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.Theratechnologies NASDAQ:THTX$2.64 +0.05 (+1.93%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$2.64 +0.00 (+0.15%) As of 05/23/2025 06:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen. Its pipeline products include F8 Formulation that is in Phase 2b/3 clinical trials for studying tesamorelin for the treatment of nonalcoholic steatohepatitis; multi -dose pen injector for the administration of tesamorelin; SORT1+ Technology Platform for the development of proprietary peptides for cancer drug development targeting SORT1 receptors; Sudocetaxel Zendusortide, which is in Phase 1 Clinical Trial for various solid tumor types, including HR+ breast, triple negative breast, ovarian, endometrial, melanoma, thyroid, small cell lung, and prostate cancers. The company was incorporated in 1993 and is headquartered in Montreal, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain Advance Auto Parts Jumps on Surprise Earnings Beat Costco Stock at $1K: Dominance or Danger Zone? Williams-Sonoma: A Fundamentally Good Buy On Sale Now Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond? Alphabet Gets JPMorgan’s Vote of Confidence After Google I/O Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
